{"product_id":"xair-vrio-analysis","title":"Beyond Air, Inc. (XAIR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Beyond Air, Inc. (XAIR) truly built to last? This VRIO analysis rigorously tests the Value, Rarity, Inimitability, and Organization of its core assets to uncover the definitive source of its competitive advantage - or where its weaknesses lie. Discover immediately below whether Beyond Air, Inc. (XAIR)'s current success is a sustainable powerhouse or just a temporary fluke.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 1. Proprietary Cylinder-Free Nitric Oxide (NO) Generation Technology (LungFit PH Platform)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of Beyond Air, Inc.'s current momentum: their cylinder-free Nitric Oxide generation tech, the LungFit PH platform. Honestly, ditching those bulky, high-pressure NO cylinders is a game-changer for hospital logistics and safety. This innovation is what's fueling their top-line acceleration right now.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick breakdown of how this proprietary technology stacks up against the VRIO criteria:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eCompetitive Implication\u003c\/th\u003e\n\u003cth\u003eKey Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity \/ Advantage\u003c\/td\u003e\n\u003ctd\u003eEliminates cylinder inventory\/handling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eFirst-to-market commercial cylinder-free generation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eRequires significant engineering expertise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage (Near-Term)\u003c\/td\u003e\n\u003ctd\u003eDrove \u003cstrong\u003e220%\u003c\/strong\u003e revenue growth in FY 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Eliminating the Cylinder Headache\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition is clear: on-demand NO generation from ambient air. This cuts out the massive logistical headache of managing, storing, and purging high-pressure NO cylinders in a hospital setting. The LungFit PH system, which operates on a standard electrical outlet, offers concentrations from 1 ppm to 80 ppm. This operational improvement translates directly into better workflow for respiratory therapists and enhanced safety, which hospitals definitely value.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity and Inimitability: The Engineering Moat\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBeing the first to commercialize a truly cylinder-free, on-demand NO generator makes this rare in the current market. It’s not just a simple tweak; it requires deep engineering to miniaturize the generation process safely. Beyond Air has protected this with more than 20 issued patents and over 10 pending. What this estimate hides, though, is that while the core tech is hard to copy quickly, a competitor could still find an alternative delivery method that bypasses the cylinder issue, which is why I peg imitability as only moderate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization and Advantage: Translating Tech to Cash\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe organization seems well-aligned to capitalize on this. They've successfully commercialized the device, leading to reported 220% revenue growth to $3.7 million for the fiscal year ended March 31, 2025. This strong execution turns the technology into a tangible advantage. For now, this is a temporary competitive advantage because the IP is strong, but you defintely need to watch for next-generation solutions that might leapfrog this one.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 2. Patented Dosing Regimens for Specific Lung Infections (e.g., NTM)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExclusive rights to novel treatment protocols for NTM lung infections.\u003c\/li\u003e\n\u003cli\u003eSupports the LungFit program, including LungFit GO for at-home NO therapy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Asset\u003c\/th\u003e\n\u003cth\u003eDetail\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGranted Patent\u003c\/td\u003e\n\u003ctd\u003eU.S. Patent No.\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12,274,830\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected Dosing Regimen\u003c\/td\u003e\n\u003ctd\u003egNO Concentration\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 ppm\u003c\/strong\u003e to \u003cstrong\u003e320 ppm\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected Dosing Regimen\u003c\/td\u003e\n\u003ctd\u003eDuration per Session\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10\u003c\/strong\u003e to \u003cstrong\u003e45 minutes\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected Dosing Regimen\u003c\/td\u003e\n\u003ctd\u003eFrequency\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e to \u003cstrong\u003e5 times per day\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected Dosing Regimen\u003c\/td\u003e\n\u003ctd\u003eDaily NO Load\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e300 ppm-hrs\u003c\/strong\u003e to \u003cstrong\u003e900 ppm-hrs\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent Expiration Date\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 12, 2038\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLegal barriers provided by granted patent protection.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIP portfolio strengthened by the latest patent issuance.\u003c\/li\u003e\n\u003cli\u003eThe Cystic Fibrosis Foundation provided a grant of up to \u003cstrong\u003e$2.17 million\u003c\/strong\u003e to help fund the completed trial of LungFit GO to treat NTM pulmonary disease in Australia.\u003c\/li\u003e\n\u003cli\u003eCompany reported \u003cstrong\u003e61\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003eFiscal year 2025 revenue guidance is \u003cstrong\u003e$12 - $16 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained advantage based on patent protection in specific treatment niches. Clinical data supports the regimen:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e15\u003c\/strong\u003e subjects enrolled in the LungFit GO pilot study for NTM.\u003c\/li\u003e\n\u003cli\u003eTotal inhalations self-administered at home: \u003cstrong\u003e2,492\u003c\/strong\u003e (as of October 2022 data cutoff).\u003c\/li\u003e\n\u003cli\u003eOverall treatment compliance: \u003cstrong\u003e\u0026gt;90%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSubjects successfully titrated to \u003cstrong\u003e250 ppm NO\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e serious adverse events related to treatment discontinuations reported.\u003c\/li\u003e\n\u003cli\u003eNO\u003csub\u003e2\u003c\/sub\u003e concentrations remained below the safety threshold of \u003cstrong\u003e5 ppm\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrevalence context: \u003cstrong\u003e13%\u003c\/strong\u003e of U.S. cystic fibrosis patients had a positive NTM culture in \u003cstrong\u003e2017\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eContrast to current standard: Antibiotic regimens can last for as long as \u003cstrong\u003etwo years\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 3. FDA-Approved Commercial Product (LungFit PH for Neonates)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides immediate revenue stream and market validation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInstalled and in regular use at more than \u003cstrong\u003e45\u003c\/strong\u003e hospitals nationwide as of June 2025.\u003c\/li\u003e\n\u003cli\u003eReported aggregate contracted revenue of over \u003cstrong\u003e$7 million\u003c\/strong\u003e through fiscal year 2027 as of August 2024.\u003c\/li\u003e\n\u003cli\u003eFiscal year ended March 31, 2025, revenue reached \u003cstrong\u003e$3.7 million\u003c\/strong\u003e, a \u003cstrong\u003e220%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; FDA approval is a high bar, but other NO delivery systems exist for neonates.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRegulatory approvals secured in the United States, European Union, Australia, Thailand, and New Zealand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; the regulatory hurdle and established installed base are hard to replicate quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe cylinder-free system eliminates the need for large, high-pressure NO cylinders.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; the commercial team is actively expanding the installed base and securing multi-year contracts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReiterated fiscal year 2026 revenue guidance between \u003cstrong\u003e$12 million\u003c\/strong\u003e and \u003cstrong\u003e$16 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected revenue for the quarter ending June 30, 2025, is at least \u003cstrong\u003e$1.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; sustained advantage depends on market penetration speed against potential future competitors.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\/Commercial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Installed Hospitals (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;45\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Annual Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2026 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12M - $16M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnounced June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAggregate Contracted Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;$7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThrough FY 2027 (as of Aug 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNO Delivery Concentration Range\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.5 ppm to 80 ppm\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor ventilated patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Market Reach\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e\u0026gt;2 billion\u003c\/strong\u003e lives\u003c\/td\u003e\n\u003ctd\u003eVia distribution partnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eThe device generates NO from ambient air on demand.\u003c\/li\u003e\n\u003cli\u003eFeatures a Smart Filter lasting \u003cstrong\u003e12 hours\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating power equivalent to a \u003cstrong\u003e60-watt\u003c\/strong\u003e light bulb.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 4. Established International Distribution Network (Access to ~2 Billion Lives)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides immediate access to massive global markets, with partnerships covering \u003cstrong\u003e18 countries\u003c\/strong\u003e, driving future revenue visibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; securing broad international partnerships quickly is challenging but not impossible for a medical device firm.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires time, capital, and relationship-building to establish these deep agreements.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; active shipments to Europe (CE Mark approval), Australia (market authorization), and the Middle East (signed agreements) show the network is operational.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; distribution agreements can be lost or superseded by competitors.\u003c\/p\u003e\n\u003cp\u003eThe established international distribution network includes the following authorized regions and partners for LungFit PH:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eCountries Covered\u003c\/td\u003e\n\u003ctd\u003eRegulatory Status Mentioned\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGetz Healthcare\u003c\/td\u003e\n\u003ctd\u003eAustralia, Hong Kong, Malaysia, New Zealand, Pakistan, Philippines, Singapore, Taiwan, Thailand, Vietnam\u003c\/td\u003e\n\u003ctd\u003eAustralia market authorization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSaudi Health Services CO\u003c\/td\u003e\n\u003ctd\u003eSaudi Arabia\u003c\/td\u003e\n\u003ctd\u003eAgreements signed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMDC Care Medical Trading\u003c\/td\u003e\n\u003ctd\u003eUnited Arab Emirates, Oman, Qatar\u003c\/td\u003e\n\u003ctd\u003eAgreements signed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUROCARE\u003c\/td\u003e\n\u003ctd\u003eFrance\u003c\/td\u003e\n\u003ctd\u003eCE Mark approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedelart Healthcare\u003c\/td\u003e\n\u003ctd\u003eTurkey\u003c\/td\u003e\n\u003ctd\u003eAgreements signed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbb Neopuls\u003c\/td\u003e\n\u003ctd\u003eRomania\u003c\/td\u003e\n\u003ctd\u003eAgreements signed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOXYPLUS\u003c\/td\u003e\n\u003ctd\u003eMorocco\u003c\/td\u003e\n\u003ctd\u003eAgreements signed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe LungFit PH system has commercial use approval in:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUnited States\u003c\/li\u003e\n\u003cli\u003eEuropean Union (CE Mark received approximately \u003cstrong\u003e15 weeks\u003c\/strong\u003e prior to March 11, 2025 announcement)\u003c\/li\u003e\n\u003cli\u003eAustralia\u003c\/li\u003e\n\u003cli\u003eThailand\u003c\/li\u003e\n\u003cli\u003eNew Zealand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context related to growth and capital supporting this network includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue in the last twelve months was reported as \u003cstrong\u003e$3.02 million\u003c\/strong\u003e or \u003cstrong\u003e$5.80 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFiscal Second Quarter 2026 revenue was \u003cstrong\u003e$1.8 million\u003c\/strong\u003e, a \u003cstrong\u003e128%\u003c\/strong\u003e year-over-year increase.\u003c\/li\u003e\n\u003cli\u003eFiscal Year 2026 revenue guidance is set between \u003cstrong\u003e$8 million\u003c\/strong\u003e and \u003cstrong\u003e$10 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2025, cash, cash equivalents, and marketable securities were \u003cstrong\u003e$10.7 million\u003c\/strong\u003e, with a proforma balance of \u003cstrong\u003e$22.9 million\u003c\/strong\u003e after a debt financing raise.\u003c\/li\u003e\n\u003cli\u003eMarket Capitalization was reported as \u003cstrong\u003e$21.38 million\u003c\/strong\u003e or \u003cstrong\u003e$9.13 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 5. Diversified Clinical Pipeline (NeuroNOS\/ASD and Beyond Cancer\/Glioma)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces reliance on the initial respiratory indication by opening up high-potential neurological and oncology markets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; having active programs in both neurological disorders (via NeuroNOS) and oncology is a unique diversification strategy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; replicating the specific partnerships (e.g., Hebrew University for ASD) and preclinical data takes time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing; the subsidiaries are in clinical\/pre-clinical stages, requiring focused management attention.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; diversification across distinct, high-need therapeutic areas creates multiple long-term value levers.\u003c\/p\u003e\n\n\u003cp\u003eThe diversification strategy is supported by distinct pipeline progress and associated financial commitments:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram Area\u003c\/th\u003e\n\u003cth\u003eTarget Indication\u003c\/th\u003e\n\u003cth\u003eDevelopment Stage\/Key Milestone\u003c\/th\u003e\n\u003cth\u003eOwnership\/Partnership\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroNOS\u003c\/td\u003e\n\u003ctd\u003eAutism Spectrum Disorder (ASD)\u003c\/td\u003e\n\u003ctd\u003ePlan to initiate first-in-human study in 2025\u003c\/td\u003e\n\u003ctd\u003eLicensing agreement with Hebrew University of Jerusalem\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeuroNOS\u003c\/td\u003e\n\u003ctd\u003eGlioblastoma (GBM)\u003c\/td\u003e\n\u003ctd\u003eReceived FDA Orphan Drug Designation (ODD) for BA-101\u003c\/td\u003e\n\u003ctd\u003eODD grants seven years market exclusivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeyond Cancer\u003c\/td\u003e\n\u003ctd\u003eSolid Tumors (UNO + ICI)\u003c\/td\u003e\n\u003ctd\u003ePhase 1a first-in-human study underway\u003c\/td\u003e\n\u003ctd\u003eBeyond Air ownership of 80% in Beyond Cancer, Ltd.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific pipeline advancements and associated financial\/regulatory data include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNeuroNOS secured initial equity financing of $2 million to accelerate preclinical development for ASD therapy.\u003c\/li\u003e\n\u003cli\u003eThe BA-102 therapy for Phelan-McDermid Syndrome (associated with ASD) anticipates a Phase 1 first-in-human trial by the end of 2026, with data potentially in 2027.\u003c\/li\u003e\n\u003cli\u003ePreclinical data for Beyond Cancer showed UNO + anti-PD-1 combination more than doubling in survival at Day 75 versus anti-PD-1 alone in a pooled analysis.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for the three months ended June 30, 2024, were $6.0 million, reflecting investment across segments including NeuroNOS ($0.1 million increase in development costs for the quarter).\u003c\/li\u003e\n\u003cli\u003eAs of June 30, 2024, the Company reported cash, cash equivalents, and marketable securities of $21.4 million.\u003c\/li\u003e\n\u003cli\u003eThe expected net cash burn rate is projected to be less than $30 million in FY 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 6. Commercial Execution \u0026amp; Scaling Capability (Hospital Adoption \u0026amp; Revenue Growth)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Translates technology into financial results, evidenced by FY 2025 revenue of \u003cstrong\u003e$3.7 million\u003c\/strong\u003e and FY 2026 guidance of \u003cstrong\u003e$12-16 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ended March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2026 Revenue Guidance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12-16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year Ending March 31, 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY2026 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Hospital Installations\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e45\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of FY2025 Report\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; many medtech firms struggle to transition from R\u0026amp;D to scaled commercial sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; the new Chief Commercial Officer has reorganized teams and is driving results, suggesting an effective, hard-to-copy sales engine.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Improving; the company is showing sequential revenue growth and increasing customer contracts by over \u003cstrong\u003e60%\u003c\/strong\u003e in one quarter.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSequential revenue growth of approximately \u003cstrong\u003e50%\u003c\/strong\u003e from the previous quarter (Q1 FY2026).\u003c\/li\u003e\n\u003cli\u003eTotal number of hospital customers increased by over \u003cstrong\u003e60%\u003c\/strong\u003e during Q2 FY2025.\u003c\/li\u003e\n\u003cli\u003eSecured a national group purchasing agreement with Premier, Inc., providing access to over \u003cstrong\u003e4,350\u003c\/strong\u003e member hospitals and health systems.\u003c\/li\u003e\n\u003cli\u003eAnnualized contracted revenue reached \u003cstrong\u003e$3.5 million\u003c\/strong\u003e as of October 1, 2024.\u003c\/li\u003e\n\u003cli\u003eCommercial expansion reaching over \u003cstrong\u003e30 countries\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; success is tied to the current commercial leadership and market acceptance rate.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 7. Second-Generation Product Development (LungFit PH2 PMA Submission)\n\u003c\/h2\u003e\n\u003cp\u003eThe submission of a Premarket Approval (PMA) supplement for the LungFit PH II system represents a strategic move to enhance the commercial offering beyond the initial FDA-approved LungFit PH device from 2022.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePromises improved product features (lighter weight, better interface) to drive market share gains and potentially capture new segments.\u003c\/p\u003e\n\u003cp\u003eThe LungFit PH II is designed to be smaller, lighter, and fully transport-ready, compatible with both air and ground transport, addressing logistical barriers.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFeature\u003c\/th\u003e\n\u003cth\u003eLungFit PH (Gen 1)\u003c\/th\u003e\n\u003cth\u003eLungFit PH II (Gen 2 - PMA Supplement)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeight\/Footprint\u003c\/td\u003e\n\u003ctd\u003eOriginal\u003c\/td\u003e\n\u003ctd\u003eReduced weight and footprint\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTransport Capability\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated as fully transport-ready\u003c\/td\u003e\n\u003ctd\u003eFull compatibility with both air and ground transport\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperation\u003c\/td\u003e\n\u003ctd\u003eStandard\u003c\/td\u003e\n\u003ctd\u003eSimplified operation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eService Intervals\u003c\/td\u003e\n\u003ctd\u003eStandard\u003c\/td\u003e\n\u003ctd\u003eLonger service intervals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBackup System\u003c\/td\u003e\n\u003ctd\u003eIntegrated backup NO delivery system\u003c\/td\u003e\n\u003ctd\u003eAutomated backup system retaining most primary system capabilities\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNO Dose Range\u003c\/td\u003e\n\u003ctd\u003e0.5 ppm – 80 ppm\u003c\/td\u003e\n\u003ctd\u003eRetains breakthrough features of the currently FDA-approved version\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePower Consumption\u003c\/td\u003e\n\u003ctd\u003eEquivalent to a 60-watt lightbulb\u003c\/td\u003e\n\u003ctd\u003eSame power consumption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate; continuous product iteration is common, but achieving a second-generation submission while commercializing the first is aggressive.\u003c\/p\u003e\n\u003cp\u003eThe first-generation device was approved by the FDA on 06\/28\/2022. The PMA supplement for the second generation was submitted in June 2025.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDifficult; requires ongoing R\u0026amp;D investment and successful navigation of the FDA resubmission process.\u003c\/p\u003e\n\u003cp\u003eResearch and development expenses for the fiscal year ended March 31, 2025, were $16.9 million compared with $24.4 million for the fiscal year ended March 31, 2024.\u003c\/p\u003e\n\u003cp\u003eThe company has a stated revenue guidance of $12 million - $16 million for fiscal year 2026.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eGood; the PMA supplement submission shows a clear, planned product roadmap.\u003c\/p\u003e\n\u003cp\u003eThe company's cash, cash equivalents, and marketable securities were $21.4 million as of June 30, 2024.\u003c\/p\u003e\n\u003cp\u003eThe company reiterated revenue guidance of at least $10 million for FY 2025.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; advantage lasts until the next-gen device is approved and adopted by the market.\u003c\/p\u003e\n\u003cp\u003eThe first-generation LungFit PH treats persistent pulmonary hypertension of the newborn (PPHN), a condition with an incidence of 1.9 per 1,000 live births and a mortality rate between 4% and 33%.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenues for the fiscal quarter ended June 30, 2024, were $0.7 million.\u003c\/li\u003e\n\u003cli\u003eRevenues for the fiscal year ended March 31, 2025, increased 220% to $3.7 million, compared with $1.2 million for the fiscal year ended March 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 8. Strengthened Balance Sheet \u0026amp; Capital Access (Cash Runway through June 2026)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial stability to execute the commercial plan and R\u0026amp;D without immediate dilution pressure, extending runway through June 2026. The Company's strengthened balance sheet is expected to provide sufficient cash runway to support current operating plans through June 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; recent capital raises, including the \\$20.6 million private placement offering, have been crucial for stability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; accessing capital from healthcare-focused institutional funds requires credibility and investor trust, as evidenced by the participation of multiple such funds in the private placement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; decisive actions were taken to manage cash burn and secure financing to support operations. Key organizational actions included the \\$20.6 million private placement and the agreement to extinguish the Avenue Capital senior secured term loan.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the runway is finite and depends on hitting revenue targets or securing future funding. The cash runway is projected through June 2026.\u003c\/p\u003e\n\u003cp\u003eThe capital structure enhancement involved several coordinated financial maneuvers:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured gross proceeds of approximately \u003cstrong\u003e\\$20.6 million\u003c\/strong\u003e from the private placement offering, priced at \\$0.51 per common share.\u003c\/li\u003e\n\u003cli\u003eAgreed to extinguish the Avenue Capital senior secured term loan for a one-time payment of \u003cstrong\u003e\\$17.85 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThis extinguishment eliminated approximately \u003cstrong\u003e\\$12 million\u003c\/strong\u003e in scheduled debt and interest payments through June 30, 2026.\u003c\/li\u003e\n\u003cli\u003eEntered into an \u003cstrong\u003e\\$11.5 million\u003c\/strong\u003e royalty funding agreement led by certain Beyond Air board members, carrying a 15% PIK interest rate until July 2026.\u003c\/li\u003e\n\u003cli\u003ePro forma cash, cash equivalents, and marketable securities following these transactions (as of September 30, 2024) was \u003cstrong\u003e\\$18.5 million\u003c\/strong\u003e, with pro forma outstanding debt of \u003cstrong\u003e\\$11.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial metrics surrounding the capital structure changes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Private Placement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$20.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember\/October 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOne-time Payment to Extinguish Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$17.85 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAvenue Capital Loan Extinguishment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt Payments Eliminated (through June 2026)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEliminated interest and principal payments\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew Royalty Funding Agreement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLed by insider investors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Burn (Q ended Sept 30, 2024, ex-financing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExcluding financing and one-time items\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro Forma Cash (Post-Financing)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$18.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro Forma Total Debt Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$10.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Burn\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Q2 ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Company's cash position and burn rate trajectory are critical to sustaining operations:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash, cash equivalents, and marketable securities were \u003cstrong\u003e\\$28.4 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eTotal debt outstanding was \u003cstrong\u003e\\$12.5 million\u003c\/strong\u003e as of September 30, 2024.\u003c\/li\u003e\n\u003cli\u003eNet loss for the quarter ended September 30, 2025, was \u003cstrong\u003e(\\$7.9) million\u003c\/strong\u003e, or a loss of \u003cstrong\u003e(\\$1.25) per share\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe net cash burn for the fiscal quarter ended September 30, 2025, was \u003cstrong\u003e\\$4.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eBeyond Air, Inc. (XAIR) - VRIO Analysis: 9. Orphan Drug Designation for Oncology Pipeline (Malignant Glioma)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Unlocks potential market exclusivity, tax credits, and faster regulatory pathways for a high-value, difficult-to-treat cancer indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; orphan designation is granted selectively for rare diseases like malignant glioma.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; the designation is granted by the FDA based on the specific disease and unmet need.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing; this is a key strategic asset for the Beyond Cancer subsidiary, showing long-term vision.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; regulatory designations like this provide long-term market protection in that specific indication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e Draft 13-week cash view by Friday.\u003c\/p\u003e\n\u003cp\u003eThe Orphan Drug Designation (ODD) for therapy BA-101 targets Glioblastoma (GBM), which is an aggressive primary brain tumor. The FDA grants ODD for diseases affecting \u003cstrong\u003efewer than 200,000 people in the U.S.\u003c\/strong\u003e. Key incentives include \u003cstrong\u003eseven years of market exclusivity\u003c\/strong\u003e upon approval, tax credits toward clinical trial costs, and prescription drug user fee waivers.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedian survival for GBM patients under current standard-of-care is \u003cstrong\u003eless than 12 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFive-year survival for GBM patients is reported as being \u003cstrong\u003ebelow 10%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe designation marks Beyond Air's entrance into oncology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.55 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 8, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eUS$10.70m\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest reported balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$30.97M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.87M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-4.7 M USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-38.22 M USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Exclusivity Period (ODD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeven years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516284231829,"sku":"xair-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/xair-vrio-analysis.png?v=1740152788","url":"https:\/\/dcf-model.com\/es\/products\/xair-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}